Implications of incretin-based therapies on cardiovascular disease
| Autor: | Tyan Thomas, Sanchita Sen, M. E. Rotz, Valerie S. Ganetsky |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Incretin Type 2 diabetes Saxagliptin Incretins chemistry.chemical_compound Diabetes management Internal medicine Diabetes mellitus medicine Humans Hypoglycemic Agents cardiovascular diseases Randomized Controlled Trials as Topic medicine.diagnostic_test business.industry General Medicine medicine.disease Treatment Outcome Endocrinology Diabetes Mellitus Type 2 chemistry Cardiovascular Diseases Albuminuria medicine.symptom Lipid profile business Mace |
| Zdroj: | International Journal of Clinical Practice. 69:531-549 |
| ISSN: | 1368-5031 |
| DOI: | 10.1111/ijcp.12572 |
| Popis: | Summary Background Incretin-based therapies offer another treatment option for patients with type 2 diabetes. Agents that provide glycaemic control in addition to attenuating cardiovascular disease (CVD) risk factors are important for diabetes management. This review will focus on the off-target effects of incretin-based therapies on CVD risk factors [body weight, blood pressure (BP), lipid profile and albuminuria], major adverse cardiovascular events (MACE), heart failure (HF) and beta-cell preservation. Methods A literature search was conducted to identify English-language publications for incretin-based therapies evaluating the following off-target end-points: body weight, BP, lipid profile, albuminuria, MACE, HF and beta-cell function. Randomised controlled trials (RCTs) were prioritised as the primary source of information. Results Overall, incretin-based therapies have shown beneficial effects on CVD risk factors, and glucagon-like peptide 1 (GLP-1) receptor agonists appear to have a more pronounced effect compared with dipeptidyl peptidase-4 inhibitors. RCTs are being conducted to determine if these positive effects on CVD risk factors translate to a reduction in MACE. To date, these studies have not shown an increase in MACE. A signal of increased hospitalisations for HF was observed with saxagliptin, warranting continued evaluation and vigilance in high-risk patients. In addition, incretin-based therapies have shown positive effects on measures of beta-cell function supporting their durability in the management of diabetes. Conclusions Incretin-based therapies are an important treatment option for patients with type 2 diabetes, offering beneficial effects on CVD risk factors without increasing MACE. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|